18 May 2015
EMA/CHMP/322484/2015
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 18-21 May 2015

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

18 May 2015, 13:00 – 19:30, room 2A

19 May 2015, 08:30 – 19:30, room 2A

20 May 2015, 08:30 – 19:30, room 2A

21 May 2015, 08:30 – 15:00, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 18-21 May 2015. See May 2015 CHMP minutes (to be published post June 2015 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 18-21 May 2015.

1.3. Adoption of the minutes

CHMP minutes for 20-23 April 2015.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. - panobinostat – Orphan - EMEA/H/C/003725

Novartis Pharmaceuticals UK Limited; treatment of multiple myeloma

Scope: Oral explanation

Action: Possible oral explanation to be held on Tuesday 19 May 2015 at time 11:00

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 25.09.2014.

Report from SAG Oncology meeting held 4 May 2015.

2.1.2. - human heterologous liver cells – Orphan / ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Oral explanation

Action: Oral explanation to be held on Wednesday 20 May 2015 at 11.00.

List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.

2.1.3. - idebenone – Orphan - EMEA/H/C/003834

Santhera Pharmaceuticals (Deutschland) GmbH; treatment of Leber's Hereditary Optic Neuropathy (LHON)

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday 19 May 2015 at 14.00.

List of Outstanding Issues adopted on 26.02.2015. List of Questions adopted on 25.09.2014.

2.1.4. - asfotase alfa - Orphan - EMEA/H/C/003794

Alexion Europe SAS; treatment of paediatric-onset hypophosphatasia

Scope: Oral explanation

Action: Oral explanation to be held on Wednesday 20 May 2015 at 9.00.

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.

~~2.1.5. - - dinutuximab – Orphan - EMEA/H/C/002800~~

~~United Therapeutics Europe Ltd; treatment of neuroblastoma, treatment of high-risk neuroblastoma~~

~~Scope: Oral explanation~~

~~**Action:** Possible oral explanation~~

~~List of Outstanding Issues adopted on 22.01.2015. List of Questions adopted on 25.04.2014~~

2.2. Re-examination procedure oral explanations

2.2.1. GVK Biosciences - - (EMEA/H/A-31/1408)

Re-examination Rapporteur: Hubert Leufkens, Re-examination Co-rapporteur: Karsten Bruins Slot

Scope: Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India following critical GCP deficiencies reported during an inspection performed by the ANSM (Agency for Medicines and Health Products Safety, France) on 19-23 May 2014.

Action: Possible Oral explanations to be held on 18 or 19 May 2015 at time xx:00,

See also 10.7.1.

Opinion adopted on 22.01.2015.

2.3. Post-authorisation procedure oral explanations

2.3.1. Perjeta - pertuzumab - EMEA/H/C/002547/II/0010

Roche Registration Ltd

Rapporteur: Christian Schneider, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Doris Stenver;

Scope: “The MAH is submitting a type II 90 day variation application to extend the use of Perjeta in combination with trastuzumab and docetaxel as part of a neoadjuvant treatment

for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer suitable for neoadjuvant therapy (tumors > 2 cm in diameter).

The submission is based primarily on the results of two randomized Phase II studies, NEOSPHERE (WO20697) and TRYPHAENA (BO22280).

The Perjeta annexes have been updated in the concerned sections as outlined in the table below and in the SmPC track change version in Module 1.3.1.

The section 4.8 Undesirable effects of the SmPC (and the section 4 of the PIL accordingly) has been revised and includes now a pooled safety analysis across the studies CLEOPATRA, the pivotal study in metastatic breast cancer, and the two neoadjuvant studies NEOSPHERE and TRYPHAENA. A“Note to the Reviewer” providing further explanations on the pooled safety analysis is also included in the track change SmPC version in Module

1.3.1.”

Action: Oral explanation to be held on Tuesday 19 May 2015 at time 09:00. For discussion

See also 5.1.5

Report by Jan Schellens from SAG Oncology meeting held on 9 March 2015.

Request for Supplementary Information adopted on 18.12.2014.

2.4. Referral procedure oral explanations

No items

3. Initial application

3.1. Initial applications; Opinions

3.1.1. - aripiprazole - EMEA/H/C/004008

~~treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder,~~

~~Scope: Opinion~~

~~**Action**: For adoption~~

~~List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014~~

Discussion in June 2015

3.1.2. - bortezomib - EMEA/H/C/003984

Treatment of multiple myeloma,

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 23.10.2014

3.1.3. - docetaxel - EMEA/H/C/003925

Treatment of breast cancer, non small cell lung cancer, prostate cancer, metastatic gastric adenocarcinoma and head and neck cancer,

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 23.10.2014.

3.1.4. - atazanavir / cobicistat - EMEA/H/C/003904

treatment of HIV-1 infected combination with other antiretroviral medicinal products

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.

3.1.5. - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.

3.1.6. - pembrolizumab - EMEA/H/C/003820

Treatment of melanoma

Scope: Opinion

Action: For adoption

List of Questions adopted on 23.10.2014.

3.1.7. - phenylephrine hydrochloride / ketorolac trometamol - EMEA/H/C/003702

Maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement (ILR) in adults

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.05.2014. List of Questions adopted on 23.01.2014.

3.1.8. - pregabalin - EMEA/H/C/003900

Treatment of epilepsy and Generalised Anxiety Disorder (GAD

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 18.12.2014.

3.1.9. - evolocumab - EMEA/H/C/003766

Hypercholesterolaemia and mixed dyslipidaemia and Homozygous familial hypercholesterolaemia

Scope: Opinion

Action: For adoption

Oral explanation held on 21 April 2015. List of Questions adopted on 22.01.2015.

~~3.1.10. - asfotase alfa - Orphan - EMEA/H/C/003794~~

~~Alexion Europe SAS; treatment of paediatric-onset hypophosphatasia~~

~~Scope: Opinion~~

~~**Action:** For adoption~~

~~List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.~~

3.1.11. - dinutuximab – Orphan - EMEA/H/C/002800

United Therapeutics Europe Ltd; treatment of neuroblastoma, treatment of high-risk neuroblastoma

Scope: Opinion / 2nd Day 180 List of Outstanding Issues

Action: For adoption

List of Outstanding Issues adopted on 22.01.2015. List of Questions adopted on 25.04.2014

3.1.12. - nivolumab - EMEA/H/C/003840

Treatment of cancer after prior chemotherapy

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 22.01.2015.

3.2. Initial applications; Day 180 list of outstanding issues

3.2.1. - isavuconazole - Orphan - EMEA/H/C/002734

Basilea Medical Ltd; Treatment of aspergillosis and mucormycosis

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 18.12.2014.

3.2.2. - p. falciparum circumsporozoite protein fused with hepatitis b surface antigen (rts), and combined with hepatitis b surface antigen (s) in the form of non-infectious virus-like particles (vlps) produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology - EMEA/H/W/002300

Indicated for active immunisation against malaria

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 20.11.2014.

~~3.2.3. - nivolumab - EMEA/H/C/003840~~

~~; treatment of cancer after prior chemotherapy~~

~~Scope: Day 180 list of outstanding issue~~

~~**Action:** For adoption~~

~~List of Questions adopted on 22.01.2015.~~

See 2.1.6

3.2.4. - pregabalin - EMEA/H/C/004024

Treatment of neuropathic pain, epilepsy and generalised anxiety disorder (GAD),

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 18.12.2014.

3.2.5. - recombinant l-asparaginase - Orphan - EMEA/H/C/002661

medac Gesellschaft fuer klinische Spezialpraeparate mbH; combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 25.04.2014.

3.2.6. - pitolisant - Orphan - EMEA/H/C/002616

BIOPROJET PHARMA; treatment of narcolepsy

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 25.09.2014.

3.2.7. - sufentanil - EMEA/H/C/002784

; indicated for the management pain

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 20.11.2014.

3.2.8. - ceftolozane / tazobactam - EMEA/H/C/003772

Treatment of intra-abdominal urinary tract infections

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 18.12.2014.

3.3. Initial applications; Day 120 list of questions

3.3.1. - atazanavir - EMEA/H/C/004048

Treatment of HIV-1,

Scope: Day 120 list of questions

Action: For adoption

3.3.2. - cinacalcet - EMEA/H/C/004014

Treatment of secondary hyperparathyroidism and hypercalcaemia,

Scope: Day 120 list of questions

Action: For adoption

3.3.3. - sacubitril / valsartan - EMEA/H/C/004062

Treatment of heart failure (NYHA class II-IV)

Scope: Day 120 list of questions

Action: For adoption

3.3.4. - lopinavir / ritonavir - EMEA/H/C/004025

Treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years,

Scope: Day 120 list of questions

Action: For adoption

3.3.5. - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982

Vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae typeb (Hib)

Scope: Day 120 list of questions

Action: For adoption

3.3.6. - lesinurad - EMEA/H/C/003932

Treatment of hyperuricaemia

Scope: Day 120 list of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. ferric citrate coordination complex - EMEA/H/C/003776

Scope: Request for revision of legal status

Action: For discussion

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 24.07.2014.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.6. Initial applications in the decision-making phase

3.7. Withdrawals of initial marketing authorisation application

3.7.1. - aripiprazole - EMEA/H/C/003926

GENERICS (UK) LIMITED;

Rapporteur: Milena Stain

Scope: Withdrawal

Action: For information

Generic application (Article 10(1) of Directive No 2001/83/EC)

Letter from the applicant dated 7 May 2015 informing of the decision to withdraw the MAA.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Somavert - pegvisomant - EMEA/H/C/000409/X/0072

Pfizer Limited;

Rapporteur: Joseph Emmerich, PRAC Rapporteur: Arnaud Batz;

Scope: "Addition of 25 mg and 30 mg powder and solvent for solution for injection."

Action: For adoption

List of Outstanding Issues adopted on 26.02.2015. List of Questions adopted on 25.09.2014.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0034/G

Vertex Pharmaceuticals (U.K.) Ltd.;

Rapporteur: Concepcion Prieto Yerro, Co-rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia;

Scope: "Line extension to the Marketing Authorisation to include a new pharmaceutical form (granules) in two new strengths (50 mg and 75 mg unit doses) to enable administration of Kalydeco to patients aged 2 to less than 6 years of age. Changes to SmPC sections 4.2, 4.4,

4.5, 4.8 and 5.2 to provide clarity and relevant updates in line with the proposed paediatric extension application. Consequential changes are made to the Package Leaflet."

Action: For adoption

List of Questions adopted on 26.02.2015.

4.2.2. Suboxone - buprenorphine / naloxone - EMEA/H/C/000697/X/0029

RB Pharmaceuticals Ltd.;

Rapporteur: Martina Weise;

Scope: "Line extension application to add 12mg/3mg and 16mg/4mg sublingual tablets."

Action: For adoption

List of Questions adopted on 22.01.2015.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Zostavax - shingles (herpes zoster) vaccine (live) - EMEA/H/C/000674/X/0085

Sanofi Pasteur MSD SNC;

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski;

Scope: "Addition of the route of administration "intramuscular" for all presentations."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0045

UCB Pharma SA;

Rapporteur: Kristina Dunder, Co-rapporteur: Agnes Gyurasics;

Scope: “Extension of indication to include treatment of severe, active and progressive rheumatoid arthritis in adults not treated previously with MTX or other disease-modifying antirheumatic drugs (DMARDs).

As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are revised in order to update the efficacy and safety information.”

Action: For adoption

5.1.2. CYRAMZA - ramucirumab - Orphan - EMEA/H/C/002829/II/0003

Eli Lilly Nederland B.V.;

Rapporteur: Pieter de Graeff, Co-rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Brigitte Keller-Stanislawski;

Scope: “Extension of Indication to include new indication for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression after platinum-based chemotherapy for CYRAMZA.

As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, one minor typographical error was corrected in section 4.2 of the SmPC.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.3. Fycompa - perampanel - EMEA/H/C/002434/II/0016

Eisai Europe Ltd.;

Rapporteur: Robert James Hemmings, Co-rapporteur: Pierre Demolis, PRAC Rapporteur: Julie Williams;

Scope: “Extension of indication as adjunctive treatment of Primary Generalised Tonic-Clonic seizures in patients with epilepsy aged 12 years and older. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to propose minor changes to PL and update the contact details of the Maltese local representative.”

Action: For adoption

Request for Supplementary Information adopted on 26.03.2015, 18.12.2014.

5.1.4. Imbruvica - ibrutinib - Orphan - EMEA/H/C/003791/II/0001

Janssen-Cilag International NV;

Rapporteur: Filip Josephson, Co-rapporteur: Christian Schneider, PRAC Rapporteur: Julie Williams;

Scope: “Extension of indication for Imbruvica for the treatment of adult patients with Waldenström Macroglobulinaemia (WM). Consequently, changes are proposed to sections

4.1, 4.2, 4.8 and 5.1 of the SmPC and to the Package Leaflet in order to incorporate all information relevant to the WM indication. In addition, some minor editorial corrections have been made in the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 26.02.2015.

~~5.1.5.~~

Discussion in June 2015.

5.1.6. Kuvan – sapropterin – EMEA/H/C/000943/II/0033 - Orphan

Merck Serono Europe Limited

Rapporteur: Patrick Salmon, Co-Rapporteur: Daniel Brasseur,

Scope: "Extension of indication for the 'treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of 4 years of age and over with phenylketonuria (PKU) who have shown to be responsive to such treatment' to include the paediatric population under 4 years old. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly."
Request for Supplementary Information adopted on 23.04.2015, 26.02.2015.

Action: For adoption

5.1.7. Perjeta - pertuzumab - EMEA/H/C/002547/II/0010

Roche Registration Ltd;

Rapporteur: Christian Schneider, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Doris Stenver;

Scope: "The MAH is submitting a type II 90 day variation application to extend the use of Perjeta in combination with trastuzumab and docetaxel as part of a neoadjuvant treatment for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer suitable for neoadjuvant therapy (tumors > 2 cm in diameter).

The submission is based primarily on the results of two randomized Phase II studies, NEOSPHERE (WO20697) and TRYPHAENA (BO22280).

The Perjeta annexes have been updated in the concerned sections as outlined in the table below and in the SmPC track change version in Module 1.3.1.

The section 4.8 Undesirable effects of the SmPC (and the section 4 of the PIL accordingly) has been revised and includes now a pooled safety analysis across the studies CLEOPATRA, the pivotal study in metastatic breast cancer, and the two neoadjuvant studies NEOSPHERE and TRYPHAENA. A"Note to the Reviewer" providing further explanations on the pooled safety analysis is also included in the track change SmPC version in Module

1.3.1."

Action: For adoption

See also 2.3.1

Request for Supplementary Information adopted on 18.12.2014.

5.1.8. Simponi - golimumab - EMEA/H/C/000992/II/0061

Janssen Biologics B.V.;

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga;

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to add a new therapeutic indication for non-radiographic axial spondyloarthritis. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 26.02.2015.

5.1.9. Stelara - ustekinumab - EMEA/H/C/000958/II/0042

Janssen-Cilag International N.V.;

Rapporteur: Greg Markey, Co-rapporteur: David Lyons, PRAC Rapporteur: Julie Williams;

Scope: "Extension of Indication to add treatment of moderate to severe plaque psoriasis in paediatric patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. As a consequence SmPC sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 have been updated and the Package Leaflet has been updated accordingly. A revised RMP version 12 was provided as part of the application."

Action: For adoption

Request for Supplementary Information adopted on 22.01.2015.

5.1.10. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0057

Takeda Austria GmbH;

Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Greg Markey, PRAC Rapporteur: Brigitte Keller-Stanislawski;

Scope: "Extension of indication for the use of Tachosil as suture line sealing in dura mater closure. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC and the Package leaflet are updated. The MAH also took the opportunity to make minor editorial corrections to the product information."

Action: For adoption

Request for Supplementary Information adopted on 22.01.2015.

5.1.11. Voncento - human coagulation factor viii / human von willebrand factor - EMEA/H/C/002493/II/0008/G

CSL Behring GmbH;

Rapporteur: Pieter de Graeff, Co-rapporteur: Greg Markey, PRAC Rapporteur: Sabine Straus;

Scope: “Extension of indication to include prophylactic treatment of patients with VWD. In addition the MAH is providing data to support treatment of paediatric patients with VWD.”

Action: For adoption

Request for Supplementary Information adopted on 18.12.2014.

5.1.12. Xultophy - insulin degludec / liraglutide - EMEA/H/C/002647/II/0002

Novo Nordisk A/S;

Rapporteur: Kristina Dunder, Co-rapporteur: Robert James Hemmings, PRAC Rapporteur: Menno van der Elst;

Scope: “Extension of indication for Xultophy to include transfer of patients from Glucagon-Like peptide-1 (GLP1) receptor agonist (RA) treatment to Xultophy. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.4, and 5.1 of the SmPC. The Package Leaflet is updated accordingly.”

Action: For adoption

Request for Supplementary Information adopted on 26.03.2015.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.3. Re-examination of Type II variation; extension of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. - H0004124

Treatment for patients with progressing advanced/metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have received prior EGFR TKI therapy

Scope: Request for an accelerated review

Action: For adoption

Rapporteurs' accelerated assessment briefing note

8.1.2. – migalastat hydrochloride-H0004059 - Orphan

Long-term treatment of adult (18 to 74 years) and adolescent (16 to 18 years) patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency) and who have an amenable genotype base as defined in: Amicus@look-uptable.com

Scope: Request for an accelerated review

Action: For adoption

Rapporteurs' accelerated assessment briefing note

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Onglyza - Saxagliptin, Saxagliptin Hydrochloride - EMEA/H/C/001039/LEG 038; Komboglyze - Metformin Hydrochloride, Saxagliptin Hydrochloride - EMEA/H/C/002059/LEG 015

AstraZeneca AB

Rapporteur: Pieter de Graeff, Co-Rapporteur: Karsten Bruins Slot, (treatment of type 2 diabetes mellitus), New active substance (Article 8(3) of Directive No 2001/83/EC)

Scope: PRAC consultation on the assessment of data on mortality from the SAVOR study, PRAC advice

Action: For discussion

9.1.2. BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0131

Pfizer Limited

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski,

Scope: Opinion or Request for supplementary information

Update of sections 4.2, 5.1, and 5.2 of the SmPC in order to update the posology with once-weekly prophylaxis regimen. The RMP is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI.

Action: For adoption

9.1.3. Labelling for medicinal products for type 2 diabetes

Rapporteur: Kristina Dunder

Scope: Response letter

Action: For discussion

Letter regarding approved labelling for medicinal products for type 2 diabetes

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

10.1.1. Tysabri - Natalizumab - EMEA/H/C/000603 /A20-0083

Biogen Idec Ltd; treatment of multiple sclerosis

Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Brigitte Keller-Stanislawski;

Scope: Procedure started at PRAC

Action: For information

Letter from the European Commission received 28 April 2015 informing of an official referral under Article 20 and its grounds.

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. GVK Biosciences - - (EMEA/H/A-31/1408)

Re-examination Rapporteur: Hubert Leufkens, Re-examination Co-rapporteur: Karsten Bruins Slot

Scope: Re-examination Opinion

Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India following critical GCP deficiencies reported during an inspection performed by the ANSM (Agency for Medicines and Health Products Safety, France) on 19-23 May 2014.

Action: For adoption

See also 2.2.1.

Opinion adopted on 22.01.2015.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003

10.10. Procedure under Article 29 Regulation (EC) 1901/2006

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

11. Pharmacovigilance issue

11.1. Early Notification System

May 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Summary of recommendations and advice of PRAC meeting held on 4-7May 2015.

Action: For information

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

13.4. Nanomedicines activities

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

None

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 4-7 May 2015

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2015

Action: For adoption

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 12-13 May 2015

Action: For information

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 4-7 May 2015

Action: For information

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at May 2015 PDCO

Action: For information

Report from the PDCO meeting held on 20-22 May 2015.

Action: For information

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 12-13 May 2015

Action: For information

14.2.6. CMDh

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 18-20 May 2015

Action: For information

14.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 4-7 May 2015. Table of conclusions

Action: For information

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

First draft of Scientific Guidance on Post-authorisation Efficacy Studies (PAES)

Action: For information

14.3.2. Quality Working Party (QWP)

Reflection paper on the use of Cocrystals of active substances in medicinal products (EMA/CHMP/CVMP/QWP/284008/2015)

Action: For adoption

14.3.3. Cardiovascular Working Party

Paediatric Addendum on the CHMP Guideline on clinical investigation of medicinal products for the treatment of acute heart failure (EMA/CHMP/707532/2013)

Action: For adoption for 6-month public consultation

Guideline on clinical investigation of medicinal products for the treatment of acute heart failure (EMA/CHMP/268124/2015)

Action: For adoption

14.3.4. Excipients Drafting Group

Questions and answers on Sodium as an excipient in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev.1) (EMA/CHMP/338679/2014)

Action: For adoption

Questions and Answers on Wheat starch (containing gluten) in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1) (EMA/CHMP/704219/2013)

Action: For adoption

Submission of comments on "Questions and answers on wheat starch (containing gluten) in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1)" - EMA/CHMP/704219/2013 (EMA/CHMP/674221/2014)

Action: For adoption

Background review for the excipient wheat starch (containing gluten) (EMA/CHMP/639441/2013)

Action: For adoption

14.3.5. Pharmacokinetics Working Party

Finalised product-specific bioequivalence guidance: last guidance from first batch

Action: For adoption

14.4. Cooperation within the EU regulatory network

14.4.1. EU Medicines Agencies Network Strategy to 2020: Working Together to Improve Health – consultation phase

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have released the 'EU Medicines Agencies Network Strategy to 2020', a draft common strategy to 2020 for the European medicines agencies network

Action: For a 3-month public consultation. Stakeholders are invited to send their comments before 30 June 2015

14.5. Cooperation with International Regulators

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

14.7. CHMP work plan

14.8. Planning and reporting

14.9. Others

15. Any other business

15.1. Revision of the Accelerated Assessment guideline

16. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/